Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 36

1.

Model Description Language (MDL): A Standard for Modeling and Simulation.

Smith MK, Moodie SL, Bizzotto R, Blaudez E, Borella E, Carrara L, Chan P, Chenel M, Comets E, Gieschke R, Harling K, Harnisch L, Hartung N, Hooker AC, Karlsson MO, Kaye R, Kloft C, Kokash N, Lavielle M, Lestini G, Magni P, Mari A, Mentré F, Muselle C, Nordgren R, Nyberg HB, Parra-Guillén ZP, Pasotti L, Rode-Kristensen N, Sardu ML, Smith GR, Swat MJ, Terranova N, Yngman G, Yvon F, Holford N; DDMoRe consortium.

CPT Pharmacometrics Syst Pharmacol. 2017 Oct;6(10):647-650. doi: 10.1002/psp4.12222. Epub 2017 Jul 12. No abstract available.

2.

Fermentation of lactose to ethanol in cheese whey permeate and concentrated permeate by engineered Escherichia coli.

Pasotti L, Zucca S, Casanova M, Micoli G, Cusella De Angelis MG, Magni P.

BMC Biotechnol. 2017 Jun 2;17(1):48. doi: 10.1186/s12896-017-0369-y.

3.

Circulating Levels of Proprotein Convertase Subtilisin/Kexin Type 9 and Arterial Stiffness in a Large Population Sample: Data From the Brisighella Heart Study.

Ruscica M, Ferri N, Fogacci F, Rosticci M, Botta M, Marchiano S, Magni P, D'Addato S, Giovannini M, Borghi C, Cicero AFG; Brisighella Heart Study Group.

J Am Heart Assoc. 2017 May 3;6(5). pii: e005764. doi: 10.1161/JAHA.117.005764.

4.

Analysis of amplicon-based NGS data from neurological disease gene panels: a new method for allele drop-out management.

Zucca S, Villaraggia M, Gagliardi S, Grieco GS, Valente M, Cereda C, Magni P.

BMC Bioinformatics. 2016 Nov 8;17(Suppl 12):339. doi: 10.1186/s12859-016-1189-0.

5.

Model-Based Assessment of Alternative Study Designs in Pediatric Trials. Part II: Bayesian Approaches.

Smania G, Baiardi P, Ceci A, Cella M, Magni P.

CPT Pharmacometrics Syst Pharmacol. 2016 Aug;5(8):402-10. doi: 10.1002/psp4.12092. Epub 2016 Aug 17.

6.

Model-Based Assessment of Alternative Study Designs in Pediatric Trials. Part I: Frequentist Approaches.

Smania G, Baiardi P, Ceci A, Magni P, Cella M.

CPT Pharmacometrics Syst Pharmacol. 2016 Jun;5(6):305-12. doi: 10.1002/psp4.12083. Epub 2016 Jun 1.

7.

A BioBrick™-Compatible Vector for Allelic Replacement Using the XylE Gene as Selection Marker.

Casanova M, Pasotti L, Zucca S, Politi N, Massaiu I, Calvio C, Cusella De Angelis MG, Magni P.

Biol Proced Online. 2016 Feb 13;18:6. doi: 10.1186/s12575-016-0036-z. eCollection 2016.

8.

Suppressor of Cytokine Signaling-3 (SOCS-3) Induces Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9) Expression in Hepatic HepG2 Cell Line.

Ruscica M, Ricci C, Macchi C, Magni P, Cristofani R, Liu J, Corsini A, Ferri N.

J Biol Chem. 2016 Feb 12;291(7):3508-19. doi: 10.1074/jbc.M115.664706. Epub 2015 Dec 14.

9.

Quantification of the gene silencing performances of rationally-designed synthetic small RNAs.

Massaiu I, Pasotti L, Casanova M, Politi N, Zucca S, Cusella De Angelis MG, Magni P.

Syst Synth Biol. 2015 Sep;9(3):107-23. doi: 10.1007/s11693-015-9177-7. Epub 2015 Aug 7.

10.

Pharmacometrics Markup Language (PharmML): Opening New Perspectives for Model Exchange in Drug Development.

Swat MJ, Moodie S, Wimalaratne SM, Kristensen NR, Lavielle M, Mari A, Magni P, Smith MK, Bizzotto R, Pasotti L, Mezzalana E, Comets E, Sarr C, Terranova N, Blaudez E, Chan P, Chard J, Chatel K, Chenel M, Edwards D, Franklin C, Giorgino T, Glont M, Girard P, Grenon P, Harling K, Hooker AC, Kaye R, Keizer R, Kloft C, Kok JN, Kokash N, Laibe C, Laveille C, Lestini G, Mentré F, Munafo A, Nordgren R, Nyberg HB, Parra-Guillen ZP, Plan E, Ribba B, Smith G, Trocóniz IF, Yvon F, Milligan PA, Harnisch L, Karlsson M, Hermjakob H, Le Novère N.

CPT Pharmacometrics Syst Pharmacol. 2015 Jun;4(6):316-9. doi: 10.1002/psp4.57. Epub 2015 Jun 15.

11.

Modelling the effects of cell-to-cell variability on the output of interconnected gene networks in bacterial populations.

Politi N, Pasotti L, Zucca S, Magni P.

BMC Syst Biol. 2015;9 Suppl 3:S6. doi: 10.1186/1752-0509-9-S3-S6. Epub 2015 Jun 1.

12.

Multi-Faceted Characterization of a Novel LuxR-Repressible Promoter Library for Escherichia coli.

Zucca S, Pasotti L, Politi N, Casanova M, Mazzini G, Cusella De Angelis MG, Magni P.

PLoS One. 2015 May 26;10(5):e0126264. doi: 10.1371/journal.pone.0126264. eCollection 2015.

13.

PhosphoHunter: An Efficient Software Tool for Phosphopeptide Identification.

Tiengo A, Pasotti L, Barbarini N, Magni P.

Adv Bioinformatics. 2015;2015:382869. doi: 10.1155/2015/382869. Epub 2015 Jan 12.

14.

In vitro chronic administration of ERbeta selective ligands and prostate cancer cell growth: hypotheses on the selective role of 3beta-adiol in AR-positive RV1 cells.

Colciago A, Ruscica M, Mornati O, Piccolella M, Montagnani-Marelli M, Eberini I, Festuccia C, Magni P, Motta M, Negri-Cesi P.

Biomed Res Int. 2014;2014:801473. doi: 10.1155/2014/801473. Epub 2014 Apr 29.

15.

A review of mixed-effects models of tumor growth and effects of anticancer drug treatment used in population analysis.

Ribba B, Holford NH, Magni P, Trocóniz I, Gueorguieva I, Girard P, Sarr C, Elishmereni M, Kloft C, Friberg LE.

CPT Pharmacometrics Syst Pharmacol. 2014 May 7;3:e113. doi: 10.1038/psp.2014.12.

16.

Half-life measurements of chemical inducers for recombinant gene expression.

Politi N, Pasotti L, Zucca S, Casanova M, Micoli G, Cusella De Angelis MG, Magni P.

J Biol Eng. 2014 Feb 1;8(1):5. doi: 10.1186/1754-1611-8-5.

17.

Forensic entomologists: an evaluation of their status.

Magni P, Guercini S, Leighton A, Dadour I.

J Insect Sci. 2013;13:78. doi: 10.1673/031.013.7801.

18.

On the myths of indicator species: issues and further consideration in the use of static concepts for ecological applications.

Zettler ML, Proffitt CE, Darr A, Degraer S, Devriese L, Greathead C, Kotta J, Magni P, Martin G, Reiss H, Speybroeck J, Tagliapietra D, Van Hoey G, Ysebaert T.

PLoS One. 2013 Oct 16;8(10):e78219. doi: 10.1371/journal.pone.0078219. eCollection 2013.

19.

White paper: landscape on technical and conceptual requirements and competence framework in drug/disease modeling and simulation.

Vlasakakis G, Comets E, Keunecke A, Gueorguieva I, Magni P, Terranova N, Della Pasqua O, de Lange EC, Kloft C.

CPT Pharmacometrics Syst Pharmacol. 2013 May 1;2:e40. doi: 10.1038/psp.2013.16.

20.

A predictive pharmacokinetic-pharmacodynamic model of tumor growth kinetics in xenograft mice after administration of anticancer agents given in combination.

Terranova N, Germani M, Del Bene F, Magni P.

Cancer Chemother Pharmacol. 2013 Aug;72(2):471-82. doi: 10.1007/s00280-013-2208-8. Epub 2013 Jun 29.

Supplemental Content

Loading ...
Support Center